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Background: MONA, which stands for a spectrum of Multicentric Osteolysis, sub-
cutaneous Nodulosis, and Athropathia, is an ultra rare autosomal recessive disorder 
caused by mutations in the matrix metallopeptidase 2 (MMP2) gene. To date only 
44 individuals, carrying 22 different mutations have been reported. Here we report 
on two brothers with identical homozygous MMP2 gene mutations, but with clearly 
different phenotypes.
Methods: Genomic DNA was isolated from the affected brothers and the parents. 
An iliac crest bone biopsy was taken from the younger patient (index case). The level 
of matrix metallopeptidase 2 enzyme (MMP2) in serum and synovial fluid of the 
younger patient was analyzed using gelatin zymography.
Results: The DNA analysis revealed a homozygous c.1188C>A transversion on 
exon 8 of the gene. The affected brothers had the same homozygous variant and the 
parents were heterozygous to this variant. This variant has been reported as a com-
pound heterozygous mutation on one individual resulting in scleroderma like skin 
thickening. Bone histomorphometry indicated increased trabecular bone remodeling 
and turnover. The zymography revealed that the level of MMP2 was completely non-
measurable in the serum and only a minor gelatinolytic protein band of about similar 
molecular weight as MMP2 was found in the synovial fluid.
Conclusions: Both the age at the onset and the phenotypic severity of the syndrome 
in these two brothers were different despite identical genotypes. The younger pa-
tients had corneal opacities leading to deteriorating visual acuity. For the first time in 
this disease, opacities were successfully treated with corneal transplantations.
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1 |  INTRODUCTION
MONA—Multicentric Osteolysis, Nodulosis, and 
Arthropathy (OMIM no. 259600)––is a rare autosomal re-
cessive disorder (Bhavani et al., 2015; Zankl et al., 2007). It 
is characterized by osteoporosis and osteolysis particularly 
in the carpal and tarsal bones, progressive joint contractures, 
and subcutaneous nodules. Such additional features as gingi-
val hypertrophy, pigmented skin lesions, coarse face, corneal 
opacities, and cardiac defects have been reported (Bhavani, 
Shah, Shukla, & Girisha, 2016; Tuysuz et al., 2009). In 
most children the onset of symptoms is between the ages of 
6 months and 6 years (Azzollini et al., 2014; Bhavani et al., 
2016). The differential diagnoses include juvenile idiopathic 
arthritis (joint contractures) and mucopolysaccharidoses 
(dysmorphic features and radiological findings) (Bhavani et 
al., 2016; Castberg et al., 2013; Zankl et al., 2007).
Multicentric Osteolysis, Nodulosis, and Arthropathy is 
caused by inactivating mutations in the matrix metallopepti-
dase2 (MMP2) gene. To date, 22 different MMP2 mutations 
associated with MONA have been reported (Bhavani et al., 
2016, 2015).
We report two siblings carrying an identical homozygous 
inactivating MMP2 mutation both diagnosed with MONA 
but with clear phenotypic differences. We also report for the 
first time bone histomorphometry findings in MONA. One of 
the siblings was treated with corneal transplantation, for the 
first time in this condition.
A two‐year‐old boy (Patient 1), the youngest of three chil-
dren, presented first with subcutaneous nodules in the gluteal 
F I G U R E  1  Patient 1 (a) at the age of 3 years and his older brother (Patient 2) (b) at the ages of 8 and 11 years both showing minor facial 
dysmorphic features: bulbous nose and frontal bossing. The younger patient (a) had joint contractures in both hands and feet. The older one (b) 
suffered from painful subcutaneous nodules in the plantar area and tendon restrictions in the hands. Radiographs demonstrate bone loss, wide 
metacarpals, and metatarsal bones
(a)
(a) (a) (b) (b)
(a) (a) (b) (b)
(b) (b)
   | 3 of 6KRÖGER Et al.
area, followed by limping and contractures of the metacarpal 
joints. He had a history of a conservatively treated lower leg 
fracture 6 months earlier.
Musculoskeletal examination revealed flexion contrac-
tures in the proximal and distal interphalangeal joints in the 
hands and feet as well as in the wrists and ankle joints. The 
skin of the soles and palms was thickened. Semiflexion in 
the knees and elbows was registered. He also had periorbital 
edema and coarse facial features (Figure 1).
Radiography of the hands and feet demonstrated widen-
ing of the tubular bones and generalized osteopenia (Figure 
1). Ophthalmological examination showed bilateral corneal 
opacities and visual impairment. An audiogram, neurode-
velopmental examination, spinal X‐ray and MRI, head MRI, 
and cardiac ultrasound were normal. MONA was confirmed 
by genetic analysis. By the age of 8  years he had suffered 
metatarsal and femoral fractures, both following minor trau-
mas. He has scoliosis and is of relatively short stature (height 
has varied from −0.1 to −1.1 SDs, BMI from −1.3 to −2.2 
SDS, and head circumference from −1.3 to 0.0 SDS). He 
developed gingival hypertrophy and pigmented skin lesions. 
During the follow‐up, joint contractures in wrists, elbows, 
knees, and ankles had progressed only slightly due to inten-
sive physiotherapy and occupational therapy and there has 
even been an improvement in the mobility of the metacarpal 
and finger joints.
During follow‐up, the opacities had progressed in both 
eyes and his right eye was operated on at the age of 4 years. 
The operation improved his vision from severely impaired 
(hand movement to light perception) to 0.08 (Snellen visual 
acuity). The pannus progressed in his left eye and was oper-
ated on later. His visual acuity at the age of 8 years was 0.4 in 
the right eye both for distance and close‐up. At the moment, 
his left eye is amblyopic but he is able to attend school with 
the help of visual rehabilitation devices and with a personal 
assistant.
This patient´s two older brothers, then aged 6 and 8 years, 
underwent clinical examination shortly after the diagnosis of 
MONA syndrome was made. The parents were not willing to 
give permission for predictive genetic testing of these chil-
dren. However, at the age of 8 years, the middle brother suf-
fered a metacarpal fracture following a minor trauma. Hand 
X‐rays showed widening and osteoporosis of the metacarpal 
bones, raising the suspicion of MONA. Furthermore, foot X‐
rays showed osteolysis and the suspicion of a healed fracture 
in the third metatarsal. After thorough discussion and consid-
eration his parents agreed to DNA testing for this child and 
the same mutation was found. On follow‐up he suffered from 
an increasing amount of subcutaneous nodules in his palms 
and soles and had developed palmar tendon restrictions. He 
has also been treated for forearm and humeral fractures. 
Some facial features such as hypertelorism and frontal boss-
ing have become more prominent (Figure 1). However the 
clinical findings are significantly milder than in his younger 
brother. He has been growing relatively well: his height −1.5 
SDS, BMI +2.4 SDS, and head circumference 0.0 SDS. Bone 
mineral density (BMD) values at the lumbar spine and femo-
ral neck were at the lower end of the age reference.
Genomic DNA was isolated from the affected brothers 
and their parents and analyzed for sequence variations in 
the MMP2 gene. The DNA analysis revealed a homozygous 
c.1188C>A transversion in exon 8 of the gene (NM_004530.5) 
resulting in S396R substitution (Figure 2). Both affected 
brothers had the same homozygous variant and the parents 
were heterozygous for the variant. This variant has been re-
cently reported as a compound heterozygous mutation in one 
individual with the MONA phenotype (Bader‐Meunier et al., 
2016). This change is also listed in the genomAD database 
with an A allele frequency of approximately 0.16% in 25,792 
Finnish chromosomes. Comparison of MMP2 amino acid se-
quences derived from numerous species show that Ser396 is 
F I G U R E  2  Chromatograms show a homozygous c.1188C>A 
mutation in the MMP2 gene
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well conserved (54/54 species). Ser396 is located in the cata-
lytic domain of the protein.
The level of matrix metallopeptidase 2 enzyme in serum 
and synovial fluid of Patient 1 was analyzed using gelatin 
zymography as described (Lohi, Lehti, Westermarck, Kähäri, 
& Keski‐Oja, 1996). Only a minor gelatinolytic protein band 
of about similar molecular weight as MMP2 was found in the 
synovial fluid and the level of MMP2 was completely non-
measurable in the serum (Figure 3).
An iliac crest bone biopsy was taken from the index 
case (Patient 1) at the age of 4. Our bone histomorphome-
try protocol, analysis, and used pediatric reference data have 
been reported previously (Glorieux et al., 2000; Mäyränpää, 
Tamminen, Kröger, & Mäkitie, 2011). Trabecular bone vol-
ume (BV/TV) was normal (20.8%, [normal mean  ±  SD, 
17.7 ± 2.6]). Osteoid volume (OV/BV 11.7% [4.0 ± 1.2]) and 
osteoid thickness (O.Th, 10.0 µm [5.8 ± 1.4]) were elevated 
and there was a large number of active osteoblasts (Ob.S/
BS, 12.2%) (8.5 ± 4.1). Osteoid surface (OS/BS) was 39.2% 
(34.0 ± 6.7). Erosion surface (ES/BS) 9.3% (14.8 ± 4.4) and 
the amount of active osteoclasts was high (Oc.S/BS, 10.0% 
[1.1 ± 0.8]). Tetracycline double labeling in vivo was per-
formed prior to biopsy. UV‐microscopy showed increased 
tetracycline uptake: mineralization surface (MS/BS, 29.7% 
[12.5 ± 4.5]), mineralization apposition rate (MAR, 1.41 µm/
day [1.0  ±  0.2]), and activation frequency (Ac.f, 4.5/year 
[1.4 ± 0.5]). Histomorphometry findings suggested increased 
trabecular bone remodeling and turnover in this patient. No 
signs of mineralization defects were detected (Figure 4).
Here we report two brothers diagnosed with MONA, 
which is an ultra‐rare disorder; only 44 cases from 27 families 
carrying 22 different mutations have been reported previously 
(Bhavani et al., 2016). Most affected individuals have carried 
homozygous mutations and are children of consanguineous 
parents. In our case, there is no known consanguinity.
Most children with MONA appear normal at birth and 
the onset of symptoms has varied from 6 months to 11 years 
(Bhavani et al., 2016). The phenotype of our younger patient was 
more severe and he was diagnosed much younger than his older 
brother. This confirms the observation that the clinical pheno-
type and the age at the onset of symptoms can vary widely in 
the presence of identical mutation (Bhavani et al., 2016, 2015).
In our younger patient, ophthalmologic examination re-
vealed broad central opacity in both eyes. Corneal opacities 
are occasionally observed in MONA patients but vision is 
normally preserved. In our patient the corneal lesions pro-
gressed and led to deteriorating visual acuity. As the progres-
sion in this patient was unusual, other etiologies cannot be 
totally excluded. Corneal transplantation was successfully 
performed with encouraging results.
Matrix metallopeptidases are extracellular zinc‐dependent 
peptidases with a role in the development and repair of the 
skeleton. MMP2 can degrade various extracellular matrix 
components of interstitial connective tissues and basement 
membranes such as collagens, fibronectin, laminin, and aggre-
can as well as extracellular soluble proteins including inflam-
matory mediators. The denaturation of collagen is important 
for collagen turnover. As bone formation and resorption are 
tightly coupled events, incomplete collagen degradation can 
cause osteoblast dysfunction and an imbalance in bone turn-
over. MMP2‐null mice have presented with decreased bone 
mineralization, articular cartilage destruction, joint erosion, 
and defects of osteoblast and osteoclast growth (Mosig et al., 
2007). However, the findings in this study are partly oppo-
site to this, since Patient 1 showed an increased bone turnover 
with profuse osteoblast and osteoclast surfaces and no signs 
of decreased mineralization. Bone biopsy was obtained from 
the iliac crest, which is the standard location for quantitative 
bone histomorphometry. It does not necessarily represent 
bone remodeling status in the affected bones. Similarly, cen-
tral bone density does not represent peripheral bone status.
MMP2 proteolytic activity measured using gelatin zymog-
raphy was completely unmeasurable in serum of our index pa-
tient, but a minor gelatinolytic protein band of similar mobility 
to MMP2 in the nonreducing gel electrophoresis for zymog-
raphy was present in the synovial fluid. Future investigation 
will be needed to assess, whether this protein band represents 
(unlikely) residual MMP2 activity, or another protease such 
as a cathepsin with gelatinolytic activity in the zymography.
Because the clinical findings in the early course of the 
disease mimic severe juvenile idiopathic arthritis many 
patients diagnosed as suffering from MONA spectrum 
F I G U R E  3  The level of matrix metallopeptidase 2 (MMP2) 
in aliquots of serum and synovial fluid from Patient 1 (index case) 
was analyzed using zymography. The level of MMP2 was very low 
in synovial fluid and was completely nonmeasurable in the serum. 
Normal human serum with abundant MMP2 activity was used as a 
control (serum aliquots of 0.5, 1, and 2 μl were used as indicated by 
the triangle; two different serum samples for the MONA index case 
were analyzed as indicated). Conditioned medium from phorphol ester 
treated (PMA; 4 nm) HT‐1080 fibrosarcoma cells served as a control 
for MMP9 and MMP2 (72 kDa pro‐form and 62 kDa active enzyme 
were separated by protein migration in electrophoresis prior to in‐gel 
activation and gelatinolysis (Lohi et al., 1996))
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disorders have previously been treated with anti‐inflam-
matory drugs, systemic corticosteroids, and methotrexate, 
naturally without long‐term beneficial effects (Castberg 
et al., 2013). As there is wide clinical variation in MONA 
syndrome, it is important to consider this hereditary disor-
der when examining patients with such joint swellings or 
contractures, which are not typical of inflammatory arthri-
tis, patients with subcutaneous nodules or even with such 
special features as thickening of the skin (Bader‐Meunier 
et al., 2016).
As there are several reports of successful bisphosphonates 
therapy in such bone diseases as osteogenesis imperfecta, the 
effect of cyclic intravenous pamidronate has been evaluated 
in children with MONA (Al‐Mayof, Madi, & Bin‐Abbas, 
2006). The treatment has been well‐tolerated but bone min-
eral density has not improved significantly and the osteolytic 
changes have not improved (Al‐Mayof et al., 2006). However, 
bisphosphonates may reduce skeletal pain and may thus be 
considered together with NSAIDs and physical therapy 
(Pichler et al., 2016).
In conclusion, MONA is an ultra‐rare severe progressive 
disease and limited data are available on its natural course 
(Bhavani et al., 2016, 2015). The variation in phenotypes 
may be wide even with identical genotypes. There is no spe-
cific alleviating treatment but multidisciplinary treatment 
may improve patients’ quality of life. Further improvements 
in understanding bone metabolism in this condition may offer 
new treatment options.
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